دورية أكاديمية
أعرض في EDS

Hypertrophic cardiomyopathy and competitive sports: let 'em play?

التفاصيل البيبلوغرافية
العنوان: Hypertrophic cardiomyopathy and competitive sports: let 'em play?
المؤلفون: Masilamani MSJ; Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA., Cannon B
المصدر: Current opinion in cardiology [Curr Opin Cardiol] 2024 Jul 01; Vol. 39 (4), pp. 308-314. Date of Electronic Publication: 2024 May 10.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams and Wilkins Country of Publication: United States NLM ID: 8608087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-7080 (Electronic) Linking ISSN: 02684705 NLM ISO Abbreviation: Curr Opin Cardiol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : Lippincott Williams and Wilkins
Original Publication: London ; New York : Gower Academic Journals, c1986-
مواضيع طبية MeSH: Cardiomyopathy, Hypertrophic*/therapy , Death, Sudden, Cardiac*/prevention & control , Death, Sudden, Cardiac*/etiology , Sports*, Humans ; Athletes ; Decision Making, Shared
مستخلص: Purpose of Review: Hypertrophic cardiomyopathy (HCM) is one of the most common cardiovascular genetic conditions. Although most patients with HCM typically do well clinically, there is a small but real incidence of sudden cardiac death. A diagnosis of HCM was previously a reason for complete exclusion in sports, particularly competitive sports.However, many of these recommendations are based on expert consensus, and much data has been published in the last decade furthering the scientific knowledge in this area, and allowing athletes who may have been previously excluded the potential to participate in strenuous activities and competitive sports.
Recent Findings: With recent publications on participation in sports with HCM, as well as an emphasis on shared decision-making, more athletes with HCM are participating in competitive sports, even at a professional level. Even contact sports in the presence of an implantable cardioverter-defibrillator are no longer mutually exclusive in the current era.
Summary: Previous guidelines were likely overly restrictive for patients with HCM. Although there is a risk of sudden death that cannot be ignored, the potential for shared decision making as well as medical guidance are entering a new era in all aspects of medicine, particularly in sports participation.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Roberts WO, Stovitz SD. Incidence of sudden cardiac death in Minnesota high school athletes 1993–2012 screened with a standardized preparticipation evaluation. J Am Coll Cardiol 2013; 62:1298–1301.
Schnell F, Riding N, O’Hanlon R, et al. Recognition and significance of pathological T-wave inversions in athletes. Circulation 2015; 131:165–173.
Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276:199–204.
Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349:1064–1075.
Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. Med Sci Sports Exerc 1994; 26: (Suppl): S261–S267.
Mitten MJ, Maron BJ, Zipes DP. Task Force 12: legal aspects of the 36th Bethesda Conference recommendations. J Am Coll Cardiol 2005; 45:1373–1375.
Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42:1687–1713.
Weissler Snir A, Connelly KA, Goodman JM, et al. Exercise in hypertrophic cardiomyopathy: restrict or rethink. Am J Physiol Heart Circ Physiol 2021; 320:H2101–H2111.
Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 2004; 141:829–834.
Corrado D, Basso C, Pavei A, et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006; 296:1593–1601.
Holst AG, Winkel BG, Theilade J, et al. Incidence and etiology of sports-related sudden cardiac death in Denmark—implications for preparticipation screening. Heart Rhythm 2010; 7:1365–1371.
Harmon KG, Drezner JA, Maleszewski JJ, et al. Pathogeneses of sudden cardiac death in national collegiate athletic association athletes. Circ Arrhythm Electrophysiol 2014; 7:198–204.
Finocchiaro G, Papadakis M, Robertus JL, et al. Etiology of sudden death in sports: insights from a United Kingdom Regional Registry. J Am Coll Cardiol 2016; 67:2108–2115.
Peterson DF, Siebert DM, Kucera KL, et al. Etiology of sudden cardiac arrest and death in US Competitive Athletes: a 2-year prospective surveillance study. Clin J Sport Med 2020; 30:305–314.
Petek BJ, Churchill TW, Moulson N, et al. Sudden cardiac death in national collegiate athletic association athletes: a 20-year study. Circulation 2024; 149:80–90.
McKinney J, Isserow M, Wong J, et al. New insights and recommendations for athletes with hypertrophic cardiomyopathy. Can J Cardiol 2024; S0828-282X:00162-4.
Pelliccia A, Caselli S, Pelliccia M, et al. Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study. Br J Sports Med 2020; 54:1008–1012.
Basu J, Finocchiaro G, Jayakumar S, et al. Impact of exercise on outcomes and phenotypic expression in athletes with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2022; 80:1498–1500.
Martinez KA, Bos JM, Baggish AL, et al. Return-to-play for elite athletes with genetic heart diseases predisposing to sudden cardiac death. J Am Coll Cardiol 2023; 82:661–670.
Schäfers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998; 82:57–62.
Lampert R, Ackerman MJ, Marino BS, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiol 2023; 8:595–605.
Aro AL, Nair SG, Reinier K, et al. Population burden of sudden death associated with hypertrophic cardiomyopathy. Circulation 2017; 136:1665–1667.
Lander BS, Phelan DM, Martinez MW, Dineen EH. Hypertrophic cardiomyopathy: updates through the lens of sports cardiology. Curr Treat Options Cardiovasc Med 2021; 23:53.
Bryde R, Martinez MW, Emery MS. Exercise recommendations for patients with hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2023; 80:53–59.
MacNamara JP, Dias KA, Hearon CM, et al. Limits to submaximal and maximal exercise in patients with hypertrophic cardiomyopathy. J Appl Physiol 2022; 133:787–797.
Asif IM, Price DE, Ewing A, et al. The impact of diagnosis: measuring the psychological response to being diagnosed with serious or potentially lethal cardiac disease in young competitive athletes. Br J Sports Med 2016; 50:163–166.
Asif IM, Price D, Fisher LA, et al. Stages of psychological impact after diagnosis with serious or potentially lethal cardiac disease in young competitive athletes: a new model. J Electrocardiol 2015; 48:298–310.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, et al. Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature. ESC Heart Fail 2023; 10:8–23.
Kon AA, Morrison W. Shared decision-making in pediatric practice: a broad view. Pediatrics 2018; 142: (Suppl 3): S129–S132.
Opel DJ. A 4-step framework for shared decision-making in pediatrics. Pediatrics 2018; 142: (Suppl 3): S149–S156.
Ardern CL, Grindem H, Ekås GR, et al. Applying ethical standards to guide shared decision-making with youth athletes. Br J Sports Med 2018; 52:1289–1290.
Boland L, Graham ID, Légaré F, et al. Barriers and facilitators of pediatric shared decision-making: a systematic review. Implement Sci 2019; 14:7.
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142:e558–e631.
Pelliccia A, Sharma S, Gati S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 42:17–96.
Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020; 142:217–229.
Norrish G, Ding T, Field E, et al. Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids). JAMA Cardiol 2019; 4:918–927.
Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2007; 115:1643–1655.
Lampert R, Olshansky B, Heidbuchel H, et al. Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation 2013; 127:2021–2030.
Lampert R, Olshansky B, Heidbuchel H, et al. Safety of sports for athletes with implantable cardioverter-defibrillators: long-term results of a prospective multinational registry. Circulation 2017; 135:2310–2312.
Griffeth EM, Dearani JA, Schaff HV, et al. Septal myectomy outcomes in children and adolescents with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 2023; 116:499–507.
Erickson CC, Salerno JC, Berger S, et al. Sudden death in the young: information for the primary care provider. Pediatrics 2021; 148:e2021052044.
Maron MS, Mitten M, Borchers J, et al. Medical and legal determinants of sports eligibility for young competitive athletes with cardiovascular disease. J Am Coll Cardiol 2023; 82:828–832.
Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44:3503–3626.
Maron MS, Rowin EJ, Maron BJ. The paradigm of sudden death prevention in hypertrophic cardiomyopathy. Am J Cardiol 2024; 212S:S64–S76.
Writing Committee Members, Silka MJ, Shah MJ, Silva JNA, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. Ann Pediatr Cardiol 2022; 15:323–346.
Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA 2018; 320:2020–2028.
Gati S, Sharma S. Exercise prescription in individuals with hypertrophic cardiomyopathy: what clinicians need to know. Heart 2022; 108:1930–1937.
تواريخ الأحداث: Date Created: 20240514 Date Completed: 20240604 Latest Revision: 20240606
رمز التحديث: 20240606
DOI: 10.1097/HCO.0000000000001148
PMID: 38743663
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-7080
DOI:10.1097/HCO.0000000000001148